A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Part of paid clinical trials in New York, New York.

Sponsor
Saakshi Khattri
Study ID
NCT04571567
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Secukinumab — DRUG
    Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe.

Study Details

This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in SOC (and its change with secukinumab treatment) as well as the effect of secukinumab on post-inflammatory hyperpigmentation and quality of life in SOC.

Key Dates

Start date
Dec 2, 2019
Status verified
Apr 2022
Primary completion
Feb 22, 2022
Completion
Feb 22, 2022

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab
    300mg subcutaneously

Primary Outcome Measure

Change in Psoriasis Area Severity Index (PASI) 90 [ Time Frame: Baseline, Week 16 and Week 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai West DermatolgyNew YorkNew York10023-

Find similar trials in New York, NY

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Mount Sinai West Dermatolgy· New York, NY

Related Studies